Plicamycin

CHEMBL1237054 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1085.1 g/mol

LogP

0.6

Phase

4

Plicamycin (mithramycin) is an antineoplastic antibiotic produced by Streptomyces plicatus that intercalates into DNA and inhibits RNA synthesis by binding to the DNA double helix in a GC-rich region, blocking the action of RNA polymerase. It was used in the treatment of testicular cancer and hypercalcemia of malignancy, and has shown activity in breast cancer and lung cancer, though its use is limited by significant toxicity.

Masse moléculaire

1085,1000 g/mol

LogP

0,60

TPSA

358,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Non-Small Cell Lung Cancer Breast Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O)[C@@H](O[C@@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@H](O)[C@@H](C)O1

InChI

InChI=1S/C52H76O24/c1-18-30(72-35-15-31(43(59)21(4)68-35)73-33-13-28(54)42(58)20(3)67-33)12-26-10-25-11-27(49(66-9)47(63)41(57)19(2)53)50(46(62)39(25)45(61)38(26)40(18)56)75-36-16-32(44(60)22(5)69-36)74-34-14-29(55)48(23(6)70-34)76-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-29,31-37,41-44,48-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,29-,31-,32-,33-,34-,35+,36+,37-,41+,42-,43-,44-,48+,49+,50+,51-,52+/m1/s1

Molecular Formula

C52H76O24

HBD / HBA

11 / 24

Liaisons Rotatives

15

Atomes Lourds

76

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Plicamycin (mithramycin) is an antineoplastic antibiotic produced by Streptomyces plicatus that intercalates into DNA and inhibits RNA synthesis by binding to the DNA double helix in a GC-rich region, blocking the action of RNA polymerase. It was used in the treatment of testicular cancer and hypercalcemia of malignancy, and has shown activity in breast cancer and lung cancer, though its use is limited by significant toxicity.

Yes, Plicamycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237054. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 163659. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Plicamycin sur PillFYI

Structure

Données Clés

Formule: C52H76O24

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.